August 6, 2026

Jia Lissa

FDA Approves Datopotamab Deruxtecan (Datroway) as Transformative First-Line Therapy for Triple-Negative Breast Cancer fda-approves-datopotamab-deruxtecan-datroway-as-transformative-first-line-therapy-for-triple-negative-breast-cancer

FDA Approves Datopotamab Deruxtecan (Datroway) as Transformative First-Line Therapy for Triple-Negative Breast Cancer

Jia Lissa June 22, 2026
WASHINGTON D.C. — In a move that marks a significant paradigm shift in the treatment of one...
Read More Read more about FDA Approves Datopotamab Deruxtecan (Datroway) as Transformative First-Line Therapy for Triple-Negative Breast Cancer
A Commitment to Discovery: President’s Dispatch Highlights the Pace of Progress and the Urgency of Funding a-commitment-to-discovery-presidents-dispatch-highlights-the-pace-of-progress-and-the-urgency-of-funding

A Commitment to Discovery: President’s Dispatch Highlights the Pace of Progress and the Urgency of Funding

Jia Lissa June 21, 2026
By Editorial Staff In the high-stakes world of medical research, the intersection of patient advocacy and scientific...
Read More Read more about A Commitment to Discovery: President’s Dispatch Highlights the Pace of Progress and the Urgency of Funding
The Genetic Blueprint of Resilience: Largest-Ever Twin Study Decodes Why We React Differently to Life’s Challenges Legs, toes, feet and heels of newborn twins. Wrapped in a knitted white blanket. Studio macro photography of the legs of newborn twins, close-up white backgraund. Two newborns.

The Genetic Blueprint of Resilience: Largest-Ever Twin Study Decodes Why We React Differently to Life’s Challenges

Jia Lissa June 21, 2026
In the complex tapestry of human psychology, one question has long confounded clinicians and researchers: Why do...
Read More Read more about The Genetic Blueprint of Resilience: Largest-Ever Twin Study Decodes Why We React Differently to Life’s Challenges
BCAL Diagnostics Advances Liquid Biopsy Frontier: New BREASTEST Monitor Targets Post-Treatment Recurrence bcal-diagnostics-advances-liquid-biopsy-frontier-new-breastest-monitor-targets-post-treatment-recurrence

BCAL Diagnostics Advances Liquid Biopsy Frontier: New BREASTEST Monitor Targets Post-Treatment Recurrence

Jia Lissa June 18, 2026
In the landscape of oncology, the period following primary breast cancer treatment is often characterized by a...
Read More Read more about BCAL Diagnostics Advances Liquid Biopsy Frontier: New BREASTEST Monitor Targets Post-Treatment Recurrence

You may have missed

a-challenging-tenure-begins-erica-schwartz-takes-the-helm-at-a-bifurcated-cdc

A Challenging Tenure Begins: Erica Schwartz Takes the Helm at a Bifurcated CDC

Reynand Wu August 6, 2026
the-erosion-of-global-health-diplomacy-an-analysis-of-the-post-usaid-landscape

The Erosion of Global Health Diplomacy: An Analysis of the Post-USAID Landscape

Reynand Wu August 6, 2026
the-quiet-revolution-reclaiming-well-being-through-the-art-of-deep-relaxation

The Quiet Revolution: Reclaiming Well-Being Through the Art of Deep Relaxation

Rifan Muazin August 6, 2026
a-new-era-for-breast-cancer-screening-pioneering-personalized-risk-assessment

A New Era for Breast Cancer Screening: Pioneering Personalized Risk Assessment

Laily UPN August 6, 2026